Last reviewed · How we verify
NCT04085783
PRP in Recurrent Implantation Failure
NA trial testing PRP in Recurrent Implantation Failure in 150 participants. Completed in 15 June 2018.
15 June 2018
Quick facts
| Lead sponsor | Dr. Kamal Rageh |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 3 December 2017 |
| Primary completion | 15 June 2018 |
| Estimated completion | 15 June 2018 |
| Sites | 1 location across Bahrain |
Drugs / interventions tested
- PRP — full drug profile →
Conditions studied
- Recurrent Implantation Failure — all drugs for Recurrent Implantation Failure →
Sponsor
Dr. Kamal Rageh
Who can join
Adults 22 to 40, female only, with Recurrent Implantation Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The endometrial function and endometrial receptivity have been accepted to be major limiting factors in the establishment of pregnancy. In spite of improved almost all aspects of IVF: ovarian stimulation, embryo culture and transfer, the pregnancy rates still not satisfactory. The bottleneck is the process of implantation. Recurrent implantation failure (RIF) is one of the nightmares in reproductive medicine and despite several strategies that have been described for management; there is no universal agreement yet. Recently, intrauterine infusion of platelet-rich plasma (PRP) is described to promote endometrial growth and receptivity, PRP has been investigated as a therapeutic approach for several medical disorders in dermatology and rheumatology, but its use in IVF is still limited. Objective: To evaluate the effectiveness of intrauterine perfusion of autologous platelet-rich plasma in the improvement of pregnancy rate in RIF patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Therapeutic roles of platelet-rich plasma to restore female reproductive and endocrine dysfunction.
Wang X, Li J, Lu W, Gao F, et al · · 2024 · cited 8× · PMID 38654928 · DOI 10.3389/fendo.2024.1374382
Verify or expand the search:
- PubMed search for NCT04085783
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PRP
Trials testing the same drug.
- NCT07453953 — A Comparison of Clinical Efficacy of Mytocel MSK With AMT and PRP Injections in Patients With Knee Osteoarthritis · EARLY_PHASE1 · not yet recruiting
- NCT07565844 — Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia · NA · recruiting
- NCT06384859 — Effectiveness of Extracorporeal Shockwave Therapy Combined With Platelet-rich Plasma in the Treatment of Chronic Inserti · Phase 4 · not yet recruiting
- NCT06339645 — Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder-A Retrospective Study · unknown
- NCT06332352 — Intra-articular Platelet-Rich Plasma for Acetabular Labral Tears · NA · completed
Other recruiting trials for Recurrent Implantation Failure
Currently open trials in the same condition.
- NCT06762626 — Comparing FET Guided by ERA Vs Standard Timing in Patients with Recurrent Implantation Failure · NA · recruiting
- NCT03900780 — Preimplantation Genetic Testing for Aneuploidies in Patients With Recurrent Implantation Failure · NA · recruiting
- NCT05169541 — Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04085783 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Kamal Rageh
- Last refreshed: 11 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04085783.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing